4.7 Article

Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 310, Issue 9, Pages 959-968

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2013.184182

Keywords

-

Funding

  1. Canadian Institutes of Health Research
  2. Heart and Stroke Foundation of Ontario
  3. Mary W Burke endowed chair of the Heart and Stroke Foundation of Ontario
  4. AstraZeneca [Sweden]
  5. AstraZeneca [Canada]
  6. Novartis
  7. Sanofi [France]
  8. Sanofi [Canada]
  9. Boehringer Ingelheim [Germany]
  10. Boehringer Ingelheim [Canada]
  11. Servier
  12. King Pharma
  13. GlaxoSmithKline
  14. Independent University, Bangladesh
  15. Mitra and Associates
  16. Unilever Health Institute, Brazil
  17. Public Health Agency of Canada
  18. Champlain Cardiovascular Disease Prevention Network
  19. Universidad de la Frontera
  20. National Center for Cardiovascular Diseases
  21. Colciencias [6566-04-18062]
  22. Indian Council of Medical Research
  23. Ministry of Science, Technology and Innovation of Malaysia [07-05-IFN-MEB010]
  24. Universiti Teknologi MARA
  25. Universiti Kebangsaan Malaysia [UKM-Hejim-Komuniti-15-2010]
  26. Polish Ministry of Science and Higher Education [290/W-PURE/2008/0]
  27. Wroclaw Medical University
  28. North-West University
  29. SANPAD (SA and Netherlands Programme for Alternative Development)
  30. National Research Foundation
  31. Medical Research Council of SA
  32. SA Sugar Association (SASA)
  33. Faculty of Community and Health Sciences (UWC)
  34. Swedish Council for Working Life and Social Research
  35. Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning
  36. Swedish Heart and Lung Foundation
  37. Swedish Research Council
  38. Swedish State under LUA Agreement
  39. Vastra Gotaland Region (FOUU)
  40. Metabolic Syndrome Society
  41. AstraZeneca, Turkey
  42. Sanofi, Turkey
  43. Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences
  44. Dubai Health Authority, Dubai UAE

Ask authors/readers for more resources

IMPORTANCE Hypertension is the most important preventable cause of morbidity and mortality globally, yet there are relatively few data collected using standardized methods. OBJECTIVE To examine hypertension prevalence, awareness, treatment, and control in participants at baseline in the Prospective Urban Rural Epidemiology (PURE) study. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study of 153 996 adults (complete data for this analysis on 142 042) aged 35 to 70 years, recruited between January 2003 and December 2009. Participants were from 628 communities in 3 high-income countries (HIC), 10 upper-middle-income and low-middle-income countries (UMIC and LMIC), and 4 low-income countries (LIC). MAIN OUTCOMES AND MEASURES Hypertension was defined as individuals with self-reported treated hypertension or with an average of 2 blood pressure measurements of at least 140/90 mm Hg using an automated digital device. Awareness was based on self-reports, treatment was based on the regular use of blood pressure-lowering medications, and control was defined as individuals with blood pressure lower than 140/90 mm Hg. RESULTS Among the 142 042 participants, 57 840 (40.8%; 95% CI, 40.5%-41.0%) had hypertension and 26 877 (46.5%; 95% CI, 46.1%-46.9%) were aware of the diagnosis. Of those who were aware of the diagnosis, the majority (23 510 [87.5%; 95% CI, 87.1%-87.9%] of those who were aware) were receiving pharmacological treatments, but only a minority of those receiving treatment were controlled (7634 [32.5%; 95% CI, 31.9%-33.1%]). Overall, 30.8%, 95% CI, 30.2%-31.4% of treated patients were taking 2 or more types of blood pressure-lowering medications. The percentages aware (49.0% [95% CI, 47.8%-50.3%] in HICs, 52.5%[95% CI, 51.8%-53.2%] in UMICs, 43.6%[95% CI, 42.9%-44.2%] in LMICs, and 40.8%[95% CI, 39.9%-41.8%] in LICs) and treated (46.7%[95% CI, 45.5%-47.9%] in HICs, 48.3%, [95% CI, 47.6%-49.1%] in UMICs, 36.9%, [95% CI, 36.3%-37.6%] in LMICs, and 31.7% [95% CI, 30.8%-32.6%] in LICs) were lower in LICs compared with all other countries for awareness (P < .001) and treatment (P < .001). Awareness, treatment, and control of hypertension were higher in urban communities compared with rural ones in LICs (urban vs rural, P < .001) and LMICs (urban vs rural, P < .001), but similar for other countries. Low education was associated with lower rates of awareness, treatment, and control in LICs, but not in other countries. CONCLUSIONS AND RELEVANCE Among a multinational study population, 46.5% of participants with hypertension were aware of the diagnosis, with blood pressure control among 32.5% of those being treated. These findings suggest substantial room for improvement in hypertension diagnosis and treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available